Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to Greg Chodaczek from the Gilmartin Group. Please go ahead.

Greg Chodaczek

Thank you, Felicia, and good afternoon, everyone. released for Bio of third TELA XXXX. today, financial the results quarter Earlier the available release website. copy press A of is on company's the

Joining Cuca, are Executive call Chief me President on Chief and Financial Tony Officer. Officer; Operating Chief Koblish, Roberto Officer and and today's

company I'd future the events. make we conference begin, that this forward-looking to like Before projections you and remind during call, may regarding statements

the XX-K review with described those the environment, results you to may strategies, the marketing resources Form Form the company's development from including, include, encourage and pipeline that filings sales without company's or identify statements. statements We capital operating in future materially COVID-XX, These and or which limitation, factors the may SEC, regulatory without XXXX factors these differ the and XX-Qs, forward-looking potential, opportunities, past events and specific product regarding to product performance. actual cause limitation, of impact

the With that, turn will I to call Tony. over

Tony Koblish

thanks today another strong afternoon, I'm that had Good Bio Greg. XXXX third TELA pleased to joining call. for for everyone, quarterly you, earnings quarter our report Thank and us performance.

revenue a was $XX.X from increase same in quarter XXXX. XX% period Third the million,

and summer seen during COVID. growth, care our contending vacations last year While to pleased put see we further health to professionals shortages, reduced potential usual products staffing with due taking having than the in full continue we surgeries to resulting them believe revenue haven't postponed as hospitals are still longer the of I after are off hours, operating

In high, opportunity. industry, substantial will market result we calls entire and see procedural gain news described of lessen, continues magnitude we quarter. the headwinds The further particular, And believe share showing to remains surgeries backlog volumes is affecting past we've these headwinds to market increased each the continue on the future OviTex notwithstanding good revenue growth. of in which

our continued growth. revenue has success driving on factors five been and Our focus the revenue driven by our

organization business compelling expansion force factors, grow size, purchasing them and into the rep product even access, group sort can productivity By of we we reporting clinical one these can sales By development. on sales These are R&D of can portfolio and improving going all today. internal data, from we revenue higher we're by forward, factors, And growth fostering potential. tap multiple revenues. growth even achieve enhancing of

Let's one take them one. by

much GPO very on track. Our efforts are access progressing

As we HealthTrust approximately place you for have and an agreement that our already of members routinely third know, in with revenues. account organization's a

Premier group was hospitals. representing the providers October that effective. purchasing signed second the recently became in day X the organization largest with and is our nation, Premier X,XXX contract XXX,XXX over

is We through success good access products rather are off start the gotten to shelf to GPO accounting to our for go process. having the a has to revenues physicians members supply use of as in a hospital committee than that to October. see it allows off organization's already sales utilization portion Premier from with noticeable our the to pleased critical our

GPO's this sales penetration align Premier to this We compensation premium with our Premier the sales contract. for the we've members goal selling incentive in the a uptake reps of long-term accelerate first and when To rate of for facilities. Hospitals, increase our force months adoption the significant six established will products believe in

the to of continuing with in increase additional U.S. also GPOs range a footprint pursue purchasers cover all contracts significant are We to to our

data. to been contributing have another advancing clinical their factor revenues We growth, also and

Society rate and and of the compelling The enable capturing low and compared repair. demonstrating high-quality We have results presented ventral American data Meeting, of recurrent believe were recurrence in been pleased OviTex of invasive studies a mainly performance rates In continue these study. to with we primary the clinical procedure market outcomes rate products. study to low share. an recurrence an recurrence for us X.X% recent OviTex open will impressively September, the from at hernia measured the Hernia competitive experienced studies, double-digit Patients in both XX-month BRAVO inguinal ventral and two hernias

in BRAVO Data Surgery. Medicine publication XX-month in recent and of seen the As our of the Annals

We surgery a continues The believe is to robot advantage use take are conducted committed procedures and of surgical recruitment we X, to system in repair. surgical setting. the a minimally supporting with on with will of of are and compiling progressing products invasive OviTex well BRAVO Today, to this additional in XX% data of which hernia focused have use positioned OviTex our a robot robotic grow, are of trend. general

we Moving are force; of we at on with on reps quarterly sales XXXX reps. finish track reached at XX XX we sales call, least to end last and to June, as our noted our in the

are We and raise August our equity of the midst process budget growing XXXX some the to sales our deploy in force. our of proceeds expect of further to

like an expansion. newest Rep our time. also quarter great had success PlaybookXX during is months We our training call. to component our continue latest on from that will looks that are indicate We've within reaching of breakeven six essential details fourth to productivity metrics more program with have reps future this process. The what three

finally, data. our We growing preparing is our selling fifth strategy will more even surgeons. the res to OviTex this a in communication case persuasive currently And are of portfolio. with aspect OviTex create materials We the anticipate based additional stakeholder product our for XX-month on make value clinical

expansion development and product product evaluate we contract partnerships also own collaborations, collaboration are strategic to and or advancing through our on acquisitions, our in with internally continue We manufacturer.

standout point them OviTex out our call to continue restoration build sales accomplished same and to as and soft force tissue preservation portfolio. products want providing We leverage additional by with the with our

in begin XXXX, and that date. additional on we'll We products a expect rolling more say to have to out later at

to third With our results. that, call financial the Roberto for details over more I'll quarter turn on

Roberto Cuca

to and grew XX% $XX.X the and period obsolete XX% excess was last the million doubled, year. year-over-year. third million, lower compared million $X.X in expense year-on-year revenue profit in for XXXX. OviTex Sales Revenue growing quarter XXXX in and increased than XXXX XXX% XX% Gross quarter same X% provision to PRS second Tony. of the was the more the year-over-year from percentage in XX% for quarter quarter. third of Thanks, sequentially of the third primarily growing increase in period was inventory. due to a same The compared XXXX to marketing $XX.X

was due mainly was G&A commercialization $X.X additional of million an in million to third expenses increase last salaries particularly primarily expense to costs quarter increase benefits This commission R&D same $X.X increased increased consulting increase as million in to was the and and due and XXXX $X.X well our employee-related expansion and third headcount of compared in both as count, result XXXX. higher and XXXX of higher and and due expense customer-facing of study due consulting quarters to the the travel period salaries roles. head a in activities, our higher as in costs the The was costs. to benefits year.

Loss million the from XXXX of quarter the Net We in $X.X operations prior year of with loss million the XXXX. $XX.X in in to was quarter period third third compared was in quarter third XXXX period. equivalents. of million the the $X.X million same $XX.X ended in and compared cash $X.X XXXX cash to million in

$XX to XX% revenue year. to we XXXX, of $XX year the continue from full the over prior for range to XX% expect to million million, Finally, growth representing

back Tony? call Tony I'll now remarks. to the for turn closing

Tony Koblish

Thanks, Roberto.

device things has proceed medical success continue to in and on to competitive just put the growth the of you've place So as expand our five to improve in plan. factors heard, and industry. continues according TELA and Bio each driving

We excellent have an exceptional in a product by customers highly price. proposition an value of functionality portfolio force. sales effective our sold offer We

Our and our published supply chain are strong substantial backed of by is volume data. clinical products a

sheet. position equity consistently such in markets. with despite to of a why in team's tenacity improvement strong the raise strong results. to August bolstered commend we When us and that an and To well we to further end, cash challenges heard investment are our address our very I'd ongoing community combined, we funded generating area The lingering impact this COVID our delivering has are was wanted on that our presents the for now is like powerful one strategy. execute performance our balance

value drivers and focus we our Looking forward, revenue will growing five on continue to growth. of

said something Finally, investors to I'd to before. like we've reiterate

of still We opportunity. us capture for are significant the products OviTex in share to is our growth. early for a tremendous of $X.X drive market room and estimate We the leaves plenty stages further which billion, future

ask operator With please to that, our questions. open I'll go your now line forward. Felicia, for the

Operator

Capital of Takkinen Frank comes [Operator Street Lake first from Instructions] the Markets. The from line question

Frank Takkinen

GPO. on Congrats the question following one wanted I on to all Tony, progress. the to comments, start and related up with Premier your the results

a talk portion Premier start pointed noticeable You on hearing? portion little accounting anecdotal in to the question, become the the you about Premier of it how long sales take more a total more something Premier, you're do Maybe with any good contract. of just said for start in October bit a early than think lines to revenue? HealthTrust feedback larger a And could for

Tony Koblish

Yes.

I very So access next we far nice so to tremendously that around those large Premier the not productive been to Premier year. much a like large going us over There's I approval. dollars news the is it's October, to in But biggest, positive the described most thus a contributed as accounts, lot. think starting are were the an array that get for of systems to be systems

going as organization to Premier. Three the time measure, think takes alluding as is to it large you're be your So to months not an I as question. with move

X,XXX setup potential. There's we of we're systems, future in like across these coordination, lot on, of working. in get a the but those lot approvals hospitals, some communication it's those going all And people a really, starting really to work of that's big and

head The is utility that category, Premier by to tough, is purchasing material, us which organization are over graduated cases which of had business that biosynthetic other Premier that a point, acknowledged array with wide likely is $XXX with tough associated from synthetic a product puts procedures. the Group that most the the of across being a which million in a means have leading at head aspect we we this to important resorbable biologics

work deal so we've to when execute we in $XX XX% all about has I million public as So of started that We've going that's difficult GPO revenue a against with us remind COVID we're will company, And during that's and period, to been HealthTrust. than sales. impaired that growth off done for propel a that big achieved you running contract that we through still to and the contract forward. us. and together the of our one but really less were far,

And way conduct HealthTrust time. quite business, forward continuing and we and with very pleased a that relationship our is we to long think for look the execution I

I And playing at in characteristic level months. we another the around attaining allow access. wide think fairly So to three will contract GPO have a field We'll that soon stages us are also of get to the access. next very early significant six

think going I So All all these work they're together, right? GPOs to together. will work

very HealthTrust hope and strong. see is HealthTrust that a I bigger. it's all between grows and race And which hoping they're one Premier I'm to

where So of that's my is sort on thought that.

we those clinical and we've opportunity maximizing got partnership of two. think a another each look tremendous together. to That's I potential because that savings. coming, partners forward significant cost one in us one to There's expect those. offer what value opportunity and in It's and do works our we the

Frank Takkinen

Got it.

for you from bigger hernia implying That's most on likely the have But from mesh picture in the right landscape. you're market. share helpful. space? market feel I on the share one a if players competitive hernia fastest-growing -- now, taking market share any maybe Okay. Obviously, taking the the multiple the was Then you're who curious on

Tony Koblish

into Well, array biologic mesh the happening but biggest plastic between mesh synthetic and and we so this Generation crosscurrents polypropylene may categories, resorbable the X in be X wider mesh. shift, we big definitely, many of expand as there's and underpenetrated we're I procedures. say would so shifts are Generation market, mesh, biologic a

around category, rates And We the it's a to economic in starting recurrence early we pronounced, biosynthetic to and to come clinical synthetic as stages both polypropylene not proposition. see are starting. and offer got a I've much better that proposition starting then our performance, value data but there. quite significant value say We're way, shift the in better

those So wave next I permanent for in and temporary. get segments, more plastic share think both that's is us to competitive the take and

Frank Takkinen

maybe for low And versus what's high just the Okay. through of maybe guide you end for the last guide? then of Can end Roberto. contemplated one the the one run

Roberto Cuca

Sure.

of effect as from not there So to COVID-XX, the continues uncertainty always, from be the order effects. now but directly second

to confirm a this quarter fourth lot cadaver we're seeing physicians physicians, we wouldn't of year who There this the had continues We last to the of hiatus. of because have a year, vacations, a to that a a taken our that vacations profession that dynamics, number or occurred three and anecdotally are know more took of who be nurses So extended couple something in of see that third not is which taking staffing two we procedures. week COVID reduced of couple nursing vacations quarter challenge. in at expect exited the a lot labs, are

they nursing get to we're And when are additional seeing how run like and done. some come is overtime might look And their that back, to manage into one will many if -- or affect thing procedures depending they in on that payments hospitals then hospitals that expenses postponing surgeries staff. that require

directly range. infections still It's could but the challenge that knock-on swing from in likely us some effects to of the just something effects. add top from be then guidance of And there's to the Southeast, So that staffing seeing is COVID the Ian. we're the not I'd Hurricane as bottom pressure that well

Operator

Our from next Piper Matthew of question O'Brien line comes of the Sandler.

Phil Dantoin

on Phil went? the Matt. elongation. you color is guess QX heard could how other for we've just vacation that so And Anecdotally, This is from for the trending QX? companies starters, on provide market Congrats in if quarter. far how I on COVID on

So are at XX% pre-COVID kind QX we was the there of And trended end a in to QX? that level that here forward below volume XX% noticeable of range. in still of step-up that's

Tony Koblish

who they at We have are last some means an running with Yes. they're I some executive and conversations not systems backlog. surgeons that in like to health the still first. still which of with going general feel below. role eating believe I'm more start into good piece we management they're had XX%, really

period projected it a So the backlog, on be going long regular right? work to backlog They're of for have a basis rolling time to a down. to up XXX% to may get

been at backlog in hernia, that think least has don't yet. I So really solved

we're being with that in spot. So at that that the is to the pretty that we and And at resolves well face the well-positioned in excellent. taking repair rolling fact that place around backlog just situated, right can the so feels product right itself grow slowly good very with well be share the we're plastic headwinds data have natural the in of right we time all the as the

Roberto Cuca

Sure.

we've We've the one fairly effects of bounce with territory, at more quarter. effect strong. QX saw the And the September, our and QX, Hurricane so caveat affect of more a July as fourth got end that Ian at cadence Southeast the some territories, some from our of did which so September some back drag-on tends and that far of of as be We vacation began that in successful seen beginning in to August.

Tony Koblish

Yes.

quarter contending quarter. that pockets fourth quarter run fourth the discussed still overall, think large, that strong, like is we usually you into weird has don't stronger. air Those ups the and started going given calm have this year, in it third I anticipate There's aren't to derivative and we by these [network] and described. downs and But up should They rise with go that the knock-on of second seem away. then effect any down. Roberto different these be to what we're

Phil Dantoin

just No, And that's still reps for added this I reps helpful. about year, pace XX it you're in finally, on so XXXX. XX call guess

reps, are -- if any a to are to it, XXXX can or appreciate your have call amount you color XXXX on and this similar yet. in insight you ahead we But Looking add to you do don't expectations? I quite XX expecting have of

Roberto Cuca

Sure.

budgeting process middle the right we now. So are of right in actually our

about up we I'd add I'd didn't and obviously our all lot them marketing. and What to the call. any is but have up more be of still on of attention the say a exact quantum if that's components is say the quarter a in fourth So building surprised reps, taking we're sales and P&L, particular we'll air, that to

Tony Koblish

our thing to to a But what I as little one thinking Yes. you add is. color will directional give

and is good remain bigger and wider. metrics productivity months, rep to the Our six three getting access

this fact are to want very the we take contracts online. of we GPO conscious come the access advantage So that as of

Operator

of comes of Genuity. Rose from line Kyle question the Canaccord Our next

Kyle Rose

And the been productivity. you little sales bit wonder to couple apologies, bounced here. a we've rep of calls around could about talk if a I more

in expected. talked beginning, cohort the think hitting earlier I the you breakeven newer than about

you So the where from maybe or the congrats early include or Does they Premier that success on most on then the the just Is PRS? contract. the that. just with are But the it side And on OviTex both PRS side seeing OviTex and can Playbook? business? of confirm traditional

Tony Koblish

Yes, contracts engaged products. we all our are for of all with are that

have the of strong say very we been cohort that's off on very starting And reps that PRS newer I the that a have cohort then So excellent. reps side. here a of got would side. are we've hernia on strong

this really one year that both on of a place, products that we're one things recall nonlinear metric of one will and sell business. more next You'll plus It's positive the impact four It's but focused rep hospital. be in one versus maybe a equals one in nothing one is that that's do one going equals to plus so focus a going is the which a aid likely productivity. forward, two roughly on

the granular learnings I classes think the this of that tend our slow to summer new to down get on, bring to time there. is Maybe just reps a good one not it's new of around So cohorts, things too them. best probably color, year, months, to not it's from train right? during

training QX through class. classes. an like have we we of run like think I certainly the end to when class. training mean, I training We think we QX a

the has certainly with a the getting now think and productivity still will stages access we're feel and encouraged we that that's But that very generate that Premier to contracts. figuring access I through out. future that better other we're in available we're of it metrics, early So even the by

So and productivity this be in very think, upside, we'll there's monitoring measures nothing going but closely, these forward. I

Kyle Rose

where you an market talk adopter you early Great. And for I broadly, here, adopters the but at PRS in perspective? technologies. data from early there's middle lot then any a the when a of not realize competitive it's are about to still of

what So some a as against just from really on upside of an -- productivity running you're up the perspective. governor from wondering

Tony Koblish

years in to in three hernia. we're comparison behind, Well, the uptake right,

access. think there's is at PRS it's interesting the future hernia again, in nothing we're do think some progression five the that stages sales business, factors, better comparison to going think by to very force, are And I well And bigger driven So the hang the I in products that going early the the of PRS very get but right, I which helpful. stronger, progressing will be looking for around to business.

under aspects, We're And lastly, it's doing significant clinical collecting really an the the study, clinical of way. it and we're retrospective a PRS amount data. data FDA right

the in So as may bit last progression. be good in one that will the business. PRS that the emerges, think elements factors in going the just earlier to help five We're the forward. four a Otherwise, around pretty I propel of PRS are of little that shape factors

much going in So early the to say still we're I'm very adopter phase.

Operator

Our next from JPM. of question comes Turkaly Dave

Dave Turkaly

on Just a commentary. follow-up the productivity

million. I there? over doing we different And folks Any million, the doing data was us sort gave Any you you've guess sales. think color over it sort first -- I number thoughts you, the doing more if of levels front of that sales of with today? a got that force know have how I but looks assume that cascade of don't $X wondering you quarter, should I are in people in $X specific of more

Roberto Cuca

Yes.

have don't we trying discussed on we've for away we're data reason that from move a us to now, that it and right Dave, So occasionally.

not performing rep, doing we'll the occasionally of we're them some stronger new more old ways period an and portion that we'll take increase for rep productivity, of time. a the providing often to this take now, occasionally economically and and harmed a one so it override, we it, territory So that subdivide a they're of holding giving

to on that to the have though, I'd the through ranks doesn't bottom even the the cut continuing to well, the in climb two we're thresholds. of see through reps, $X.XX We're level, from is to work territory an unsubdivided at continuing more we're quickly continuing with to that And the forward, end, than X.X So territories newer get going more points. doing past. the million see the as measure the say, them million, larger. and just quite pass under million the $X.X reps $X see we our What

Tony Koblish

if say X you quantity, Yes. we're that with of that. and look $X I'd pretty pleased even the million all progression, at with

Dave Turkaly

a sort building I terms rate the Got on can the follow-up, us just you this some was And it. Roberto, quick been the know And maturity? if maybe then just then inventory. wondering debt, I remind you've like you sort out that level any level is you for is think [indiscernible], COVID now these level. comment we're particularly ahead, that normal moving of of getting have headwinds there hopefully as you of of what kind on but the

Roberto Cuca

Sure.

me let with inventory. start So the

going So is the going expect inventory more grow do to similarly forward revenues. weight of we that to

stock-ins Over to do some inventory had the to disruptions, particularly potential in Europe. past for year, prepare we

that we're does. should at Again, base bigger a inventory rate same revenue now revenues. more So as of grow the the closely at

far facility payments. up expect It's for of three As all-in years debt that different of course easy couple fifth types four interest an can of which order is over we years year. to to be X% something meet. on there's rate interest-only into or if are years, we chopped two the the the either meet thresholds, one a of goes, facility year the to pretty which as And then amortization extended certain last the

Operator

of line question, final Weiner comes from Jefferies. Zach of next the our Our and next question

Zach Weiner

on Congrats on to just quarter. again. another good I wanted touch backlog

capture. or comment haven't much a you made seen You that backlog

talk is bit? to how large you you -- as recapture a backlog that about think up these headwinds ease if we curious and backlog of start about could So how some

Roberto Cuca

Sure.

can So I'll jump Tony and then in. start

hernia was including the order immediately [that XXX,XXX actual then way we to that the backlog know, hospital seeing. checked sounds before that variance growth cases repairs measure then a from out] the the who rate we measure trends that on COVID the then estimated look in physicians So we and with take some in administrators the we at hernia and And confirmed are of that some trend right. the

if going patients of the into you're the as backlog new the you and coming to backlog. Now, think inventory, essentially going out about get backlog an patients

point the if at the you're doing doing was down not And were procedures be rate backlog you're same at that going backlog even established, lower continue before not a it you Tony's and rate, them the may as to working was you're to grow.

So what we levels, from over, and patients the had same substantially. is have means on continues size be of hearing of backlog of backlog, the that turned been the decreased seeing not hospitals it in to has the though order the may and XX% rate which physicians individual the not are that pre-COVID even

Tony Koblish

to to have much don't add that. I

Zach Weiner

and Okay. following that? the Any guess OviTex combination? backlog on helpful Very on the or appreciate that, I up consists comprehensive. it. is I color mostly PRS, of

Tony Koblish

I Yes. mean, It's is a say to cancer hernia. animal. different connected mostly would PRS surgery. it's I

different be there. to I going So think there's a approach

Roberto Cuca

Yes.

are we've on be reconstruction like to are looked you can't tends with the had One larger some delayed with during commented to hospital which surgeries cancer, But patients disruptions cases the observation of one emergent. delay more PRS which were resilient breast they those whereas The cases market COVID, are them. have really surgeries even connected is that were from heard is As gotten we talked more to you become able because as delayed. serious. to that when and be seeing were COVID that tears priority administrators can much mastectomies past associated repairing point they hernia they that calls, the what until delay them we they hernia

Zach Weiner

on know some quickly going it. you're trial said to how just -- And about Can look enroll Got of like That's timelines there? you give should study then what to and you think is starting kind the or that we in. what I on X. that helpful. BRAVO color

Tony Koblish

Absolutely.

study So do other hospitals was clinical on. going significantly was list to a X high post-market many priority not COVID, delayed much on when so a BRAVO stuff by

So we're double-digit that. think We're coming the I now. in out of enrollment

starting group it's of whole move. we're that And -- are it on think I coming a board. have sites We see new to

I exactly can be will enrollment know when any don't I complete. give So on color when

think and these see couple I of sites of that. new before a quarters got how can do maybe more we we've to performance perform

do subcomponent looking confirmatory I So do of we're we're cases out patients think now. to at right emphasize are I There one that total done mostly and which done position want XX% study. in to laparoscopically BRAVO a right is minimally day done of in But X that done are robotic are another BRAVO invasively. XX% robotically. and don't XX% thing It's our now, is a for But as day in robotic a nature. of within a X, were

for a array types. case a wide array So that surgeons series X,XXX wide is we've data studies, single-arm hernia of then there. And got over of well patients registries, in various from

And BRAVO what seeing with rates exactly those X, signals clinical digits. are data low, recurrence we're single and low

we've I robotic data simple the excellent enough portfolio a we've product got lot an that in most we've think got the proof source period. filled And that to of most procedures. show complicated procedures during COVID from this So in to everything for

So we made good the use time. of

X out report I So will on BRAVO it. think

I think robotic study, procedure back it's us things, to think great I right some be and MIS grouping. don't We'll and going holding going interesting be a very it's confirmatory. in now like feel I it's the but learn to

Zach Weiner

we've through whatnot other a or this areas could put Any Just have color that extended I'll numbers something certainly been way had and of could appreciate in some of around where heard it been one I more how you more during where the and on me, -- much that summer, think tech. revenue try. vacations the med growth quarter? impacted you quarter normalized for

Roberto Cuca

Sure.

all tricky couple occurring are time. that's there because the of one a are to So pretty at dynamics that estimate a same

the is, staffing of total of desire suppressed overtime. by number obviously, one procedures been them have So that by to avoid possible

that not of challenge procedure prior proportionally that roughly distributed same levels. necessarily is that, so The And you the to gets that's XX% way.

hearing less surgeries, been hernia we've prioritizing knee would more of include is the So replacements hospitals the that of surgeries, replacement, at lucrative expense which hip things lucrative so have been one repair.

the prioritization the may total of lucrative of be some in again, those, So surgeries vacations. over that of some our are surgeries number and taking procedures because dynamic a the of more of be reduction may place it just

that. very is. to up that's to for us much make of We come difficult of confident a way really an that a is the been effects that pretty saying So long how just that's of quarter. it's for contributing one can't the that, estimate number We're with

Operator

time, I like call comments. would the for At over the any to to back additional this turn further speakers

Tony Koblish

Felicia, joining and for Bio. evening, you thank thank and you, for in TELA your interest us Thank this you

We in of continuation here the it's XX next growth now. the XX to early ramping much forward to definitely right be I the look months. is a great of team this We're to place over The our excited. very and and this are company inside stages very very business motivated,

thank you. So

Operator

you conference. conclude today's for Thank your participation program. in This the does

disconnect. You may now

TELA Bio (TELA) 9 Nov 222022 Q3 Earnings call transcript